Calcium Chloride Dihydrate

證據等級: L5

預測適應症: 0 個

Calcium Chloride Dihydrate: Evaluation Report – No Active Repurposing Prediction Available

One-Sentence Summary

Calcium Chloride Dihydrate is an inorganic calcium salt with well-established clinical utility in electrolyte replacement and cardiac emergencies. The TxGNN model has returned no repurposing predictions for this compound, and the drug currently holds no SAHPRA registration in South Africa. Due to blocking data gaps and the absence of any prediction output, this candidate cannot proceed to standard evaluation at this time.

Quick Overview

Item	Content
Original Indication	Not recorded in this Evidence Pack
Predicted New Indication	None – TxGNN returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	L5 (model prediction only; no predictions generated)
South Africa Market Status	Not marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

No repurposing prediction is available for Calcium Chloride Dihydrate in this Evidence Pack. As a result, no mechanistic reasoning for a new indication can be provided at this stage.

Currently, detailed mechanism of action data is not available. Based on general pharmacological knowledge, Calcium Chloride Dihydrate is an inorganic calcium salt that provides ionised calcium for physiological processes including cardiac muscle contraction, nerve conduction, and blood coagulation. Its established clinical roles include management of hypocalcaemia, hyperkalaemia-induced cardiac arrhythmia, and magnesium toxicity.

A repurposing evaluation can only be initiated once the TxGNN pipeline produces at least one ranked prediction and the blocking data gap (DG001: SAHPRA/TFDA-equivalent Professional Information) is resolved.

Clinical Trial Evidence

Currently no related clinical trials registered for a repurposing indication, as no predicted indication has been generated.

Literature Evidence

Currently no related literature available for a repurposing indication.

South Africa Market Information

Calcium Chloride Dihydrate is currently not registered with SAHPRA and has no active product licences on record in this Evidence Pack.

Healthcare professionals should note that calcium chloride preparations (e.g., for intravenous resuscitation use) may be available through hospital formularies or importation pathways under Section 21 authorisation from SAHPRA, but no formal product registration exists in this dataset.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information once a registered product is identified. Report adverse drug reactions to SAHPRA via the MedSafety portal.

The following data gaps prevent a complete safety assessment at this time:

Gap ID	Category	Missing Item	Severity	Impact
DG001	Drug Level	SAHPRA/TFDA Professional Information – warnings and contraindications	Blocking	Cannot complete safety pre-screening (Stage 1)
DG002	Drug Level	Mechanism of action (MOA)	High	Cannot perform mechanistic relevance analysis

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN model produced no repurposing predictions for this compound, and a blocking data gap (absence of any SAHPRA-registered Professional Information) prevents safety pre-screening from proceeding. Without both a prediction target and foundational safety data, this candidate cannot advance in the evaluation pipeline.

To proceed, the following is needed:

Resolve DG001 (Blocking): Obtain the SAHPRA-approved or TFDA Professional Information PDF; parse for warnings, contraindications, and special populations. Without this, the candidate is ineligible for Stage 1 safety review.
Resolve DG002 (High): Query the DrugBank API using the compound name “Calcium Chloride Dihydrate” to retrieve the DrugBank ID, MOA, pharmacodynamics, and drug interaction data.
Re-run the TxGNN prediction pipeline: Investigate why no predictions were generated – possible causes include a missing DrugBank ID mapping (noted as null in this pack), which would prevent the compound from being matched to the knowledge graph. Once the DrugBank ID is confirmed, re-run the KG and DL prediction modules.
Confirm SAHPRA registration pathway: If a repurposing candidate is later identified, initiate a Section 21 or full registration dossier review, noting that no existing SAHPRA licence can be leveraged for label expansion.

This report is generated for research purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before any therapeutic application. Prepared using TxGNN Evidence Pack v4 (data cutoff: 4 April 2026).

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.